Natixis Advisors LLC Grows Stock Position in argenx SE (NASDAQ:ARGX)

Natixis Advisors LLC grew its position in shares of argenx SE (NASDAQ:ARGX) by 13.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,014 shares of the company’s stock after buying an additional 1,379 shares during the period. Natixis Advisors LLC’s holdings in argenx were worth $6,513,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. O Shaughnessy Asset Management LLC boosted its holdings in argenx by 32.8% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 1,460 shares of the company’s stock worth $575,000 after buying an additional 361 shares during the period. Advisors Asset Management Inc. boosted its holdings in shares of argenx by 79.3% in the 1st quarter. Advisors Asset Management Inc. now owns 588 shares of the company’s stock worth $232,000 after purchasing an additional 260 shares in the last quarter. Toronto Dominion Bank grew its position in argenx by 16.5% during the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after acquiring an additional 43 shares during the last quarter. Silvercrest Asset Management Group LLC grew its holdings in shares of argenx by 14.2% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 5,184 shares of the company’s stock valued at $2,041,000 after purchasing an additional 646 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of argenx by 24.8% in the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after buying an additional 439,889 shares during the period. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several analyst reports. Baird R W downgraded shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Wedbush increased their target price on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a research report on Tuesday, November 12th. Oppenheimer reiterated an “outperform” rating and set a $675.00 price objective (up previously from $646.00) on shares of argenx in a research note on Thursday. Finally, Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $515.00 to $650.00 in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $630.42.

argenx Trading Up 1.5 %

NASDAQ ARGX opened at $605.92 on Friday. argenx SE has a 12 month low of $327.73 and a 12 month high of $611.22. The stock has a market cap of $36.23 billion, a PE ratio of -693.08 and a beta of 0.61. The stock’s 50 day moving average is $556.37 and its 200 day moving average is $486.73.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. On average, analysts forecast that argenx SE will post 2.2 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.